One-pot regioselective synthesis of tetrahydroindazolones and evaluation of their antiproliferative and Src kinase inhibitory activities by Rao, V. Kameshwara et al.
University of Rhode Island
DigitalCommons@URI
Biomedical and Pharmaceutical Sciences Faculty
Publications Biomedical and Pharmaceutical Sciences
2012
One-pot regioselective synthesis of
tetrahydroindazolones and evaluation of their
antiproliferative and Src kinase inhibitory activities
V. Kameshwara Rao
Bhupender S. Chhikara
University of Rhode Island
See next page for additional authors
Creative Commons License
Creative Commons License
This work is licensed under a Creative Commons Attribution-Noncommercial-No Derivative Works 4.0
License.
Follow this and additional works at: https://digitalcommons.uri.edu/bps_facpubs
This is a pre-publication author manuscript of the final, published article.
This Article is brought to you for free and open access by the Biomedical and Pharmaceutical Sciences at DigitalCommons@URI. It has been accepted
for inclusion in Biomedical and Pharmaceutical Sciences Faculty Publications by an authorized administrator of DigitalCommons@URI. For more
information, please contact digitalcommons@etal.uri.edu.
Citation/Publisher Attribution
Rao, V. K., Chhikara, B. S., Tiwari, R., Shirazi, A. N., Parang, K., & Kumar, A. (2012). One-pot regioselective synthesis of
tetrahydroindazolones and evaluation of their antiproliferative and Src kinase inhibitory activities. Bioorganic & Medicinal Chemistry
Letters, 22(1), 410-414. doi: 10.1016/j.bmcl.2011.10.124
Available at: https://doi.org/10.1016/j.bmcl.2011.10.124
Authors
V. Kameshwara Rao, Bhupender S. Chhikara, Rakesh Tiwari, Amir Nasrolahi Shirazi, Keykavous Parang, and
Anil Kumar
This article is available at DigitalCommons@URI: https://digitalcommons.uri.edu/bps_facpubs/124
Chapman University
Chapman University Digital Commons
Pharmacy Faculty Articles and Research School of Pharmacy
2012
One-Pot Regioselective Synthesis of
Tetrahydroindazolones and Evaluation of Their
Anti-proliferative and Src Kinase Inhibitory
Activities
V. Kameshwara Rao
Defence Research & Development Establishment
Bhupender S. Chhikara
University of Rhode Island
Rakesh Tiwari
Chapman University, tiwari@chapman.edu
Amir Nasrolahi Shirazi
Chapman University, shirazi@chapman.edu
Keykavous Parang
Chapman University, parang@chapman.edu
See next page for additional authorsFollow this and additional works at: http://digitalcommons.chapman.edu/pharmacy_articles
Part of the Cell Biology Commons, Medical Biochemistry Commons, and the Medical Cell
Biology Commons
This Article is brought to you for free and open access by the School of Pharmacy at Chapman University Digital Commons. It has been accepted for
inclusion in Pharmacy Faculty Articles and Research by an authorized administrator of Chapman University Digital Commons. For more information,
please contact laughtin@chapman.edu.
Recommended Citation
Rao, V. K., Chhikara, B.S., Tiwari, R., Nasrolahi Shirazi, A., Parang, K., Kumar, A. One-pot regioselective synthesis of
tetrahydroindazolones and evaluation of their anti-proliferative and Src kinase inhibitory activities. Bioorg. Med. Chem. Lett. (2012) 22,
410-414.
DOI:10.1016/j.bmcl.2011.10.124
One-Pot Regioselective Synthesis of Tetrahydroindazolones and
Evaluation of Their Anti-proliferative and Src Kinase Inhibitory Activities
Comments
NOTICE: this is the author’s version of a work that was accepted for publication in Bioorganic & Medicinal
Chemistry Letters. Changes resulting from the publishing process, such as peer review, editing, corrections,
structural formatting, and other quality control mechanisms may not be reflected in this document. Changes
may have been made to this work since it was submitted for publication. A definitive version was subsequently
published in Bioorganic & Medicinal Chemistry Letters, volume 22, in 2012. DOI: 10.1016/j.bmcl.2011.10.124
Copyright
Elsevier
Authors
V. Kameshwara Rao, Bhupender S. Chhikara, Rakesh Tiwari, Amir Nasrolahi Shirazi, Keykavous Parang, and
Anil Kumar
This article is available at Chapman University Digital Commons: http://digitalcommons.chapman.edu/pharmacy_articles/104
 One-pot regioselective synthesis of tetrahydroindazolones and 
evaluation of their anti-proliferative and Src kinase inhibitory 
activities 
V. Kameshwara Rao,a Bhupender S. Chhikara,b Rakesh Tiwari,b Amir Nasrolahi 
Shirazi,b Keykavous Parangb,* Anil Kumara,* 
aDepartment of Chemistry, Birla Institute of Technology and Science, Pilani 333031, Rajasthan, India 
bDepartment of Biomedical and Pharmaceutical Sciences, College of Pharmacy, University of Rhode Island, Kingston, RI, 
02881, USA 
This is where the receipt/accepted dates will go; Received Month XX, 2000; Accepted Month XX, 2000 [BMCL RECEIPT] 
Abstract—A number of 2-substituted tetrahydroindazolones were synthesized by three-component condensation reaction of 1,3-
diketones, substituted hydrazines, benzaldehydes, and Yb(OTf)3 as a catalyst in [bmim][BF4] ionic liquid using a simple, efficient, and 
economical one-pot method. The synthesized tetrahydroindazolones were evaluated for inhibition of cell proliferation of human colon 
carcinoma (HT-29), human ovarian adenocarcinoma (SK-OV-3), and c-Src kinase activity. 3,4-Dichlorophenyl tetrahydroindazolone 
derivative (15) inhibited the cell proliferation of HT-29 and SK-OV-3 cells by 62% and 58%, respectively. 2,3-Diphenylsubstituted 
tetrahydroindazolone derivatives, 19, 25, and 33, inhibited the cell proliferation of HT-29 cells by 6572% at a concentration of 50 μM. 
In general, the tetrahydroindazolones showed modest inhibition of c-Src kinase where 4-tertbutylphenyl- (32) and 3,4-dichlorophenyl- 
(13) derivatives showed the inhibition of c-Src kinase with IC50 values of 35.1 μM and 50.7 μM, respectively. 
Multi-component reactions (MCRs) have emerged as 
a powerful synthetic strategy in organic and medicinal 
chemistry to generate structurally diverse libraries of 
drug-like molecules.1 MCRs offer significant 
advantages over conventional linear-type syntheses, 
such as being rapid and one-pot reactions without the 
need to generate and purify intermediates. 
Tetrahydroindazolones (THIs) have a broad 
spectrum of biological and pharmacological activities.2 
Compounds with indazoles and indazolones scaffolds 
have been reported to exhibit herbicidal,3 anti-
inflammatory,4 anticancer,5 and antituberculosis 
activities.6 A tetrahydroindazolone scaffold containing 
SNX-2122 (a, Fig. 1) is a heat-shock protein 90 (HSP-
90) inhibitor,5a and it exhibits potent antiproliferative 
activities against HER2-dependent breast cancer cells.5b 
Tetrahydroindazole-based compound (b) in Fig. 1 is a 
potent inhibitor of Mycobacterium tuberculosis 
(MTB).6a  
 
Figure 1. Chemical structures of lead compounds containing 
tetrahydroindazolone scaffolds (a) SNX-2122: HSP90 inhibitor; (b) MTB 
inhibitor.  
Combretastatin A-4 (CA4) (Fig. 2) is a potent 
antiproliferative agent which acts through interaction 
with microtubules. Analogues of CA4 and several other 
derivatives where cis-double bond was replaced with a 
tetrazole, thiazole, imidazole, or oxazole rings have 
been synthesized and studied for evaluation of 
anticancer activities and establishing structure-activity 
relationships.7,8 THIs have also been previously reported 
possessing antitumor activity.9 The synthesized THIs 
have structural resemblance to the tetrazole, triazole, 
imidazole, or oxazole derivatives of CA4 that were 
shown to exhibit potent cytotoxicity and anti-tumor 
activity.7,8 We hypothesized that incorporation of 
crucial structural features of CA4 and THIs may 
generate lead compounds with anticancer properties 
(Fig. 2).  
Furthermore, phenylpyrazolopyrimidine derivatives, 
such as PP1 and PP210 have been reported as inhibitors 
of the Src family of tyrosine kinases (SFKs) that play 
prominent roles in multiple signal transduction 
pathways, which involve cell growth and 
differentiation. The nine members of non receptor SKFs 
(Src, Yes, Lck, Fyn, Lyn, Fgr, Hck, Blk, and Yrk) share 
a great deal of structural homology and are present in 
the cytoplasm.11 The expression of Src tyrosine kinase, 
the prototype of SFKs, is frequently elevated in a 
number of epithelial tumors compared with the adjacent 
normal tissues. Src reduces cancer cell adhesions and 
facilitates their motility,12 thus it is a key modulator of 
cancer cell invasion and metastasis.13 Heterocyclic THIs 
 have some structural similarity with 
phenylpyrazolopyrimidine derivatives (Fig. 2), and were 
investigated to determine whether they can mimic PP1 
or PP2. 
 
Figure 2. Structural relativity of THIs to Combrestatin A-4 mimics and 
phenylpyrazolopyrimidines as anticancer agents and Src kinase inhibitors, 
respectively. 
In continuation of our efforts towards the synthesis 
of small molecules as anticancer agents and/or c-Src 
kinase inhibitors,14 herein we report the synthesis and 
evaluation of an array of 33 synthesized diversely 
substituted THIs. 
The most common method for the synthesis of THIs 
is simple condensation of arylhydrazines with 2-
acylcyclohexane-1,3-diones.15 However, this method 
results in regioisomeric mixtures of 
tetrahydroindazolone. There are only very a few 
methods for the synthesis of 2-substituted THIs. 
Separation of 2-substituted THIs from a mixture of 
isomers is challenging and, therefore, these compounds 
have not been much explored for biological activity. We 
have previously reported the synthesis of other 
heterocyclic compounds through MCRs catalyzed by 
metal triflates.16 One-pot three component regioselective 
synthesis of substituted THIs catalyzed by ytterbium 
triflate [Yb(OTf)3] in 1-butyl-3-methylimidazolium 
tetrafluoroborate ([bmim][BF4]) ionic liquid is shown in 
Scheme 1. 
In a protocol standardization experiment, when 5,5-
dimethylcyclohexane-1,3-dione (2), 4–chloro-
benzaldehyde (2), and 3,4-dichlorophenyl hydrazine (3) 
were reacted in ethanol at room temperature in presence 
of Yb(OTf)3 (20 mole %), the product 4 (R1 = Me, X = 
C, R2 = 3,4-Cl2Ph, R3 = 4-ClPh) (see AD for general 
synthesis in Scheme 1) was obtained in 20% yield. 
Further optimization of reaction condition was carried 
out by changing solvents, catalysts, and catalyst 
loading. As shown in Table 1, the use of 20 mol% 
Yb(OTf)3 in [bmim][BF4] gave the desired product 4 in 
high yield (88%) (entry 4). When Yb(OTf)3 was 
changed with other metal triflates such as Sc(OTf)3, 
Zn(OTf)2, Cu(OTf)2 or AgOTf the yield of 4 was 
moderate to good (Table 1, entries 7-10). The catalytic 
order Yb(OTf)3 > Zn(OTf)2 > Sc(OTf)3 > Cu(OTf)2 > 
AgOTf was established for the synthesis of 4 based on 
isolated yield in [bmim][BF4]. There was not much 
increase in yield of 4 on changing the amount of 
Yb(OTf)3 from 20 mol% to 40 mol% (Table 1, entries 
4-6). However, reducing the amount of Yb(OTf)3 
decreased yield of 4 to 51%. It should be noted that no 
product formation was observed in solvent free 
conditions; however 45% of 4 was formed in the 
absence of Yb(OTf)3. The structure of the compound 4 
was confirmed by 1H NMR, 13C NMR, and mass 
spectrometry. In 1H NMR three singlet peaks were 
observed at δ 2.81, 2.42 and 1.16 ppm for C7-CH2, C5-
CH2, and C6-(CH3)2, respectively along with other 
aromatic protons. It is worthy to mention that under 
these conditions only 2-substituted 
tetrahydroindazolones were obtained. 
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Scheme 1. Synthesis of substituted tetrahydroindazolones. 
 
Table 1. Optimization of reaction conditions for the model 
reaction.  
S. 
No 
Catalyst Moles (%) Solvent 
Time 
(h) 
Yield 
(%)a 
1 Yb(OTf)3 0 [bmim][BF4] 2.00 45 
2 Yb(OTf)3 10 - 2.00 NPb 
3 Yb(OTf)3 10 [bmim][BF4] 2.00 51 
4 Yb(OTf)3 20 [bmim][BF4] 2.00 88 
5 Yb(OTf)3 30 [bmim][BF4] 2.00 90 
6 Yb(OTf)3 40 [bmim][BF4] 2.00 89 
7 Zn(OTf)2 20 [bmim][BF4] 2.00 70 
8 Ag(OTf) 20 [bmim][BF4] 2.00 50 
9 Sc(OTf)3 20 [bmim][BF4] 2.00 60 
10 Cu(OTf)2 20 [bmim][BF4] 2.00 56 
11 Yb(OTf)3 20 [bmim][PF6] 2.00 65 
12 Mont. K-10 20 Ethanol 2.00 20 
13 pTSA 20 Ethanol 2.00 20 
14 Yb(OTf)3 20 Ethanol 2.00 20 
15 Yb(OTf)3 20 Toluene 2.00 NA 
16 Yb(OTf)3 20 THF 2.00 NA 
aIsolated yield, bNo product formed 
Under the optimized reaction conditions, various 
arylhydrazines, arylaldehydes, and 1,3-diones 
 underwent one-pot reaction and afforded the 
corresponding 2-substituted THIs (436) (Table 2). 
Various benzaldehydes and arylhydrazines with electron 
withdrawing and donating substituents, such as nitro, 
halo, hydroxyl, methoxy, alkyl, and aryl, were used to 
establish the structure-activity relationships. 
Table 2: Synthesized 2-substituted THIs (436). 
X
X N
N
O
R3
R2
R1
R1
 
Compd R1 X R2 R3 
Yield 
(%)a 
4 CH3 C 3,4-Cl2C6H3 4-ClC6H4 88 
5 CH3 C 3,4-Cl2C6H3 4-NO2C6H4 85 
6 CH3 C 3,4-Cl2C6H3 C4H3S 73 
7 CH3 C 3,4-Cl2C6H3 4-CH3C6H4 83 
8 CH3 C 3,4-Cl2C6H3 3-OH,4-OMeC6H3 65 
9 CH3 C 3,4-Cl2C6H3 4-OHC6H4 70 
10 CH3 C 3,4-Cl2C6H3 C4H4N 80 
11 CH3 C 3,4-Cl2C6H3 4-OMeC6H4 74 
12 CH3 C 3,4-Cl2C6H3 C6H5 75 
13 CH3 C 3,4-Cl2C6H3 3-ClC6H4 82 
14 H C 3,4-Cl2C6H3 4-ClC6H4 82 
15 H C 3,4-Cl2C6H3 C4H3S 71 
16 H C 3,4-Cl2C6H3 4-CH3C6H4 78 
17 H C 3,4-Cl2C6H3 2-FC6H4 77 
18 H C 3,4-Cl2C6H3 4-OMeC6H4 70 
19 H C 3,4-Cl2C6H3 C6H5 72 
20 H C 3,4-Cl2C6H3 4-OHC6H4 65 
21 H C 3,4-Cl2C6H3 3-OH,4-OMeC6H3 60 
22 H C 3,4-Cl2C6H3 4-NO2C6H4 84 
23 H C 3-Cl, 4-CH3C6H3 3-OMeC6H4 77 
24 CH3 C 3-Cl, 4-CH3C6H3 4-ClC6H4 81 
25 CH3 C 3-Cl, 4-CH3C6H3 C5H4N 69 
26 CH3 C 3-Cl, 4-CH3C6H3 C4H4N 54 
27 CH3 C C6H11 C4H3S 78 
28 CH3 C C6H11 4-NO2C6H4 80 
29 CH3 O C6H11 4-ClC6H4 50 
30 H C C6H11 3-ClC6H4 76 
31 H C C6H11 4-CH3C6H4 76 
32 CH3 C 4-(CH3)3CC6H4 4-OMeC6H4 77 
33 CH3 C 4-(CH3)3CC6H4 3,4-(OMe)2C6H3 81 
34 CH3 C 4-(CH3)3CC6H4 4-ClC6H4 77 
35 CH3 O 4-(CH3)3CC6H4 4-ClC6H4 48 
36 CH3 C 4-(CH3)3CC6H4 4-CH3C6H4 79 
aIsolated yield 
The chemical structures of all synthesized 
compounds were elucidated by 1H NMR, 13C NMR, and 
mass spectroscopy (Supporting information). A single 
peak for two protons of C7-carbon at around 2.8 ppm 
confirmed formation of only a single isomer. These 
values are in agreement with the literature report for 
regioselective formation of 2-substituted THIs.15d 
Furthemore, regioselective formation of 2-substituted 
THIs was confirmed by X-ray crystalographic data for 
compound 6 (CCDC 848784) and 27 (CCDC 850178). 
The ORTEP view for compound 6 (Fig 3A) and 27 (Fig 
3B) clearly shows that 3,4-dichlorophenyl and 
cyclohexyl group are at N-2 position in 6 and 27, 
respectively. 
(A) (B) 
 
 
Figure 3. ORTEP view of molecular structure of compound (A) 6 and 
(B) 27. 
The regioselective formation of N-2-substituted THI 
indicates that hydrazine first attacks at carbonyl group 
of diketone. Based on the product formation the reaction 
is believed to proceed through the formation of 
hydrazone followed by attack of aldehyde to give aldol 
product, which undergoes nucleophilic addition as 
shown in Scheme 2. It appears that ionic liquid helps in 
stabilization of charged intermediate generated by 
coordination of Yb(OTf)3 to aldehydes and diones. 
Furthermore, the acidic C-2 proton of imidazolium ionic 
liquid also facilitates the enolization of dione.  
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Scheme 2: Plausible mechanism for synthesis of THIs. 
All the synthesized compounds (436) were 
evaluated for their effect on proliferation of ovarian 
adenocarcinoma cells (SK-OV-3) and colon 
adenocarcinoma (HT-29), two human cancer cells lines 
that overexpress c-Src.17 Doxorubicin (Dox) and DMSO 
were used as positive and negative controls, 
respectively. The results for cell proliferation at 50 µM 
after 72 h for compound 430 are shown in Fig. 4. All 
the compounds were more active against HT-29 
 cells than SK-OV-3 cells. Compounds 19, 25, and 
33 inhibited the cell proliferation of HT-29 cells by 65-
72% while they were not effective against SK-OV-3. 
Compounds 15, 16, and 27 showed 48-62% and 49-58% 
inhibition in the cell proliferation of HT-29 and SK-
OV-3 cells, respectively. The presence of C4H3S- 
substituent as R3 or 3,4-dichlorophenyl or tolyl as R2 is 
critical for maximum anti-proliferative activity as seen 
in compounds 15 and 16. 
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Figure 4. Inhibition of HT-29 and SK-OV-3 cell proliferation by compounds 433 (50 µM) after 72 h incubation. The results are shown as the percentage 
of the control DMSO that has no compound (set at 100%). All the experiments were performed in triplicate.
Synthesized substituted THIs were evaluated for c-
Src kinase inhibitory activity. The results of Src kinase 
inhibitory activity of compounds (433) are shown in 
Table 3. Among all the compounds, 12, 13, 19, 30, 31, 
and 32 showed modest inhibition of Src kinase with 
IC50 values in the range of 35-69 µM.  
Compounds 32 and 13 were found to show the 
highest Src kinase inhibitory activities with IC50 values 
of 35.1 and 50.7 M, respectively, among all the 
compounds. Molecular modeling and minimization of 
compounds 32 and 13 was used to explore and compare 
with the binding mode of these compounds when 
compared with PP1 within the ATP-binding site of the 
enzyme (Fig. 5). The backbone tetrahydroindazolone in 
32 and 13 and pyrazolopyrimidine in PP1 occupied a 
similar pocket in ATP-binding site of Src. The 
modeling studies indicated that 3,4-dichlorophenyl and 
4-(tert)butylphenyl at R2 position in 13 and 32, 
respectively, occupy and fit the hydrophobic binding 
pocket similar to tolyl group of PP1 with slightly 
different orientations of phenyl groups (Fig. 5). The 4-
methoxyphenyl and 3-chlorophenyl at R3 position of 32 
and 13, respectively, are oriented far from the large 
cavity that is formed from side chains of helix αC and 
helix D, where the triphosphate group of ATP usually 
binds similar to that of t-butyl group of PP1, thus 
suggesting that substitution at R3 position of THIs does 
not generate any advantageous in Src kinase inhibition 
through interactions with adjacent amino acids in the 
ATP binding site. 
Table 3. Src kinase inhibitory activity of substituted 
THIs (436).  
Compd. IC50 (µM)a Compd. IC50 (µM)a 
4 86.0 22 150 
5 150 23 82.7 
6 150 24 131.8 
7 150 25 74.3 
8 150 26 150 
9 66.6 27 77.3 
10 150 28 150 
11 94.1 29 150 
12 62.1 30 58.4 
13 50.7 31 57.7 
14 81.0 32 35.1 
15 150 33 150 
16 150 34 150 
17 150 35 150 
18 150 36 150 
19 65.8 rniropsoruato  0.6 
20 150 PP2 0.5 
21 150   
aThe concentration at which 50% of enzyme activity is inhibited. 
 These data suggest that further structural 
modifications in tetrahydroindazolone scaffold is 
required to convert them to more potent Src kinase 
inhibitors such as phenylpyrazolopyrimidine derivatives 
PP1 and PP2. Poor correlation between inhibition of Src 
kinase and the cell proliferation could be due to the 
differential cellular uptake and alternative mechanisms 
in anti-proliferative activities of the compounds.  
 
 
Figure 5. Comparison of structural complexes of Src kinase with 
different THIs derivatives. 32 (yellow), PP1 (blue), and 13 (red)) based 
on molecular modeling. The compounds and side chains of amino acids 
are rendered in stick styles. Compounds are in the lowest energy 
conformers predicted. The Figure is drawn using the Accelrys 
visualization system. 
In conclusion, an ecofriendly and regioselective 
method was developed for the synthesis of 2-substituted 
THIs by one-pot three-component coupling reaction of 
benzaldehydes, arylhydrazines, and 1,3-diones using 
Yb(OTf)3 as a catalyst in ionic liquid. To the best of our 
knowledge, this is the first report of one-pot synthesis 
and evaluation of THIs as Src kinase inhibitors and 
anticancer agents. The synthesized compounds were 
evaluated for c-Src kinase inhibitory activity and 
compound 32 showed moderate inhibition of Src kinase 
with IC50 value of 35.1 µM. Compounds 15 and 16 
consistently inhibited the cell proliferation of SK-OV-3 
and HT-29 cells by 49-62% at a concentration of 50 
μM. Further structure-activity relationship studies are 
required for optimizing the Src kinase inhibition and 
anti-proliferative activities of THIs. 
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